Business
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS)
About this update from Viatris Inc.
[{"type":"text","content":"Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS)\nPITTSBURGH, April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27. Data will include results from the pivotal Phase III clinical trial exploring the efficacy and safety of GA Depot – a long-acting glatiramer acetate being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).\n\"Viatris' commitment to developing GA Depot as a potential treatment for multiple sclerosis (MS) patients is driven by our belief that access is fundamental to empowering people worldwide to live healthier at every stage of life,\" said Abhijit Barve, Chief Medical Officer, Viatris. \"Through this ongoing research, we are applying our industry-leading expertise and experience to develop novel treatment options that support and more holistically address the needs of the MS community. That's why we are excited to be back at the American Academy of Neurology meeting this year and proud to partner with Mapi Pharma to showcase the latest clinical data on GA Depot.\"\n\"The American Academy of Neurology meeting is an important forum to share with the neurology community the results of the study which show the potential of GA Depot 40 mg to offer patients with relapsing forms of multiple sclerosis an effective treatment option,\" said Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma.\nVisit Viatris at AAN at booth #761 to learn more about the study and how the company supports the needs of the MS community. GA Depot data will be presented during the following poster session:\nResults of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four WeeksSpeaker: Aaron E. Miller, MD, FAANApril 24th, 5:30 – 6:30 p.m. ESTPoster Session P6, Poster #014Boston Convention and Exhibition Center, Exhibit Hall B2, Neigh...